+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
T-Cell Immunotherapy Market - Global Forecast 2026-2032- Product Image
T-Cell Immunotherapy Market - Global Forecast 2026-2032- Product Image
Sale

T-Cell Immunotherapy Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986070
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The T-Cell Immunotherapy Market is projected to reach USD 8.57 Billion in 2026. It is expected to continue growing at a CAGR of 8.34%, reaching USD 13.90 Billion by 2032.

T-cell immunotherapy has moved from a specialized hematology innovation to a core pillar of precision oncology, led by CAR T-cell therapy, T-cell receptor therapies, tumor-infiltrating lymphocyte therapy, and next-generation engineered T-cell platforms. The clinical rationale is well established: T cells can recognize malignant cells, expand in vivo, and generate durable immune memory when appropriately activated, selected, or engineered.

Market momentum is supported by a rising global cancer burden, with IARC’s GLOBOCAN 2022 estimating about 20 million new cancer cases and 9.7 million cancer deaths worldwide. Since the first U.S. FDA approvals of CAR T-cell therapies in 2017, the field has expanded across lymphoma, leukemia, multiple myeloma, and melanoma, while research pipelines increasingly target solid tumors, autoimmune disease, and off-the-shelf allogeneic approaches. This evolution positions T-cell immunotherapy as a strategically important segment of cancer immunotherapy, advanced therapy medicinal products, and personalized medicine.

Transformative Shifts in the T-Cell Immunotherapy Landscape

The T-cell immunotherapy landscape is being reshaped by clinical validation, manufacturing industrialization, and a shift from late-line rescue therapy toward earlier treatment settings. FDA-approved products such as Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Amtagvi demonstrate that engineered or selected T cells can deliver meaningful responses in selected cancers, while label expansions continue to broaden eligible patient populations.

The next transformation is operational. Developers and healthcare systems are investing in closed-system manufacturing, cryopreservation, decentralized collection networks, and improved release testing to reduce vein-to-vein time. At the same time, allogeneic T-cell therapies, gene-editing tools, dual-target constructs, safety switches, and armored CAR designs are being evaluated to address relapse, antigen escape, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cost barriers in the T-cell immunotherapy landscape.

Cumulative Impact of Artificial Intelligence on T-Cell Immunotherapy

Artificial intelligence is increasingly influencing T-cell immunotherapy across discovery, clinical development, manufacturing, and patient monitoring. AI-enabled bioinformatics can support antigen discovery, T-cell receptor selection, neoantigen prioritization, and prediction of tumor immune escape, particularly when integrated with genomics, transcriptomics, proteomics, spatial biology, and single-cell sequencing data.

In manufacturing, machine learning can help identify process variables linked to cell phenotype, expansion, potency, and batch consistency. In clinical practice, AI can support patient selection, toxicity risk stratification for cytokine release syndrome or neurotoxicity, imaging review, and real-world evidence generation. The cumulative impact is not a replacement for biological validation; it is a faster, data-driven framework for designing safer, more scalable, and more personalized T-cell therapies while strengthening quality control and clinical decision support.

Key Regional Insights Across Global T-Cell Immunotherapy Markets

North America remains the most mature region for T-cell immunotherapy, supported by FDA regulatory experience, major academic cancer centers, payer frameworks, and a deep biotechnology financing ecosystem. The United States leads adoption and clinical trial density, while Canada benefits from coordinated cancer networks, provincial health technology assessment processes, and growing cell therapy infrastructure.

Europe is advancing through EMA-approved advanced therapy medicinal products, national reimbursement pathways, cross-border research networks, and strong manufacturing capabilities in Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is one of the fastest-developing regions, led by China’s high clinical trial volume, Japan’s regenerative medicine framework, South Korea’s biomanufacturing strength, India’s cost-focused innovation, and Australia’s translational research networks.

Latin America, the Middle East, and Africa are earlier in commercialization but strategically important for long-term access. Brazil and Mexico are building oncology access, referral networks, and trial capacity; Middle Eastern health systems, particularly in high-investment Gulf countries, are expanding specialized hospitals, genomic medicine, and advanced oncology services; and African markets are prioritizing partnerships, diagnostics, hematology-oncology infrastructure, workforce training, and referral pathways to expand access to T-cell immunotherapy over time.

Key Group Insights for T-Cell Immunotherapy Adoption

ASEAN is emerging as a regional growth corridor for T-cell immunotherapy as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines strengthen oncology care, clinical research, regulatory capacity, and medical tourism services. The region’s opportunity is tied to affordability, quality-assured cell processing, regional referral pathways, regulatory harmonization, and partnerships with global and local cell therapy stakeholders.

The European Union provides a structured environment for advanced therapy medicinal products through centralized EMA review, pharmacovigilance requirements, health technology assessment alignment, and cross-border research funding. The GCC is investing in high-acuity cancer centers, precision medicine, genomics programs, and international hospital partnerships, creating a foundation for advanced cell therapy adoption in selected tertiary care settings.

BRICS countries are important for patient scale, manufacturing diversification, clinical development, and cost innovation, particularly China, India, and Brazil, while South Africa and Russia contribute scientific capability and regional access considerations. G7 countries continue to anchor clinical evidence generation, reimbursement debate, regulatory precedent, and specialized treatment-center networks. NATO countries overlap significantly with advanced Western healthcare systems, supporting supply chain resilience, research collaboration, cold-chain readiness, and biomanufacturing security for cell and gene therapies.

Key Country Insights Shaping T-Cell Immunotherapy Growth

The United States is the global benchmark for commercial CAR T-cell therapy adoption, clinical trials, FDA precedent, accredited treatment centers, and real-world evidence generation. Canada is expanding access through provincial reimbursement decisions, coordinated cancer agencies, and academic manufacturing initiatives, while Mexico is developing specialized oncology services, private-sector access pathways, and cross-border collaboration. Brazil leads Latin America in clinical research capacity, hematology-oncology expertise, and cancer center infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong oncology systems with active health technology assessment, managed access programs, and hospital-based treatment expertise. Germany and France remain important for advanced therapy manufacturing and reimbursement evaluation, the United Kingdom supports early access and clinical research infrastructure, and Italy and Spain are strengthening regional treatment-center networks. Russia maintains scientific and clinical capabilities but faces access, financing, and international collaboration constraints.

In Asia-Pacific, China has become a major clinical development hub for CAR T-cell therapy, supported by large patient populations, active investigator-led studies, and expanding regulatory experience. India is advancing cost-efficient indigenous cell therapy models and local manufacturing approaches, Japan benefits from a supportive regenerative medicine environment and established oncology care, South Korea is strong in biologics and cell therapy manufacturing, and Australia supports early-phase translational research through leading cancer institutes, public health research funding, and clinical trial networks.

Actionable Recommendations for T-Cell Immunotherapy Leaders

Industry leaders should prioritize evidence generation that demonstrates durable response, overall survival benefit, manageable toxicity, quality-of-life improvement, and real-world value versus existing standards of care. Earlier-line indications, solid tumor programs, autoimmune applications, and combination strategies should be pursued with disciplined biomarker strategies, robust companion diagnostic planning, and clear patient-selection criteria.

Executives should also invest in scalable manufacturing, digital chain-of-identity and chain-of-custody systems, automated quality control, validated potency assays, and resilient cryogenic logistics. Partnerships with academic centers, hospitals, payers, contract development and manufacturing organizations, diagnostic laboratories, and public health stakeholders can reduce commercialization friction. To improve access, organizations should evaluate outcomes-based reimbursement, regional manufacturing hubs, technology transfer models, and tiered market strategies that align advanced T-cell immunotherapy innovation with health system affordability.

Research Methodology for T-Cell Immunotherapy Analysis

This executive summary is based on secondary research from publicly available, authoritative sources, including regulatory agency disclosures, clinical trial registries, peer-reviewed oncology literature, health technology assessment documents, treatment guidelines, and global cancer statistics from recognized public health organizations. Evidence was cross-checked across multiple sources to ensure accuracy and to avoid unsupported market estimation, sizing, share, or forecasting claims.

The research framework assessed approved therapies, pipeline direction, regional regulatory environments, reimbursement trends, manufacturing models, technology adoption, and clinical development activity. Insights were synthesized using qualitative market analysis, competitive benchmarking, regulatory review, and healthcare system assessment, with emphasis on data-backed developments in CAR T-cell therapy, TCR therapy, TIL therapy, allogeneic cell therapy, gene-edited cell therapy, and AI-enabled cell therapy innovation.

Conclusion: The Next Era of T-Cell Immunotherapy

T-cell immunotherapy is entering a new phase defined by broader clinical use, more sophisticated engineering, and increasing pressure to improve access, cost, safety, and scalability. Approved CAR T-cell and TIL therapies have validated the therapeutic potential of living medicines, while next-generation platforms aim to extend benefit into solid tumors, earlier lines of care, and selected immune-mediated diseases.

The field’s long-term progress will depend on manufacturing efficiency, biomarker-driven development, payer confidence, global infrastructure, equitable referral pathways, and responsible integration of artificial intelligence. Organizations that combine rigorous science with operational excellence, regulatory discipline, and access-focused commercialization will be best positioned to lead the next era of oncology immunotherapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. T-Cell Immunotherapy Market, by Therapy Type
7.1. Introduction
7.2. CAR-T Therapy
7.3. TCR Therapy
7.4. TIL Therapy
8. T-Cell Immunotherapy Market, by Cell Source
8.1. Introduction
8.2. Allogeneic Cells
8.3. Autologous Cells
9. T-Cell Immunotherapy Market, by Target Antigens
9.1. Introduction
9.2. BCMA Targeting
9.3. CD19 Targeting
9.4. CD22 Targeting
10. T-Cell Immunotherapy Market, by Manufacturing Method
10.1. Introduction
10.2. Ex-Vivo
10.3. In-Vivo
11. T-Cell Immunotherapy Market, by Patient Type
11.1. Introduction
11.2. Adult Patients
11.3. Pediatric Patients
12. T-Cell Immunotherapy Market, by Indication
12.1. Introduction
12.2. Autoimmune Diseases
12.2.1. Lupus
12.2.2. Rheumatoid Arthritis
12.3. Hematological Malignancies
12.3.1. Leukemia
12.3.2. Lymphoma
12.3.3. Myeloma
12.4. Solid Tumors
12.4.1. Brain & Central Nervous System
12.4.2. Liver Cancer
12.4.3. Melanoma
13. T-Cell Immunotherapy Market, by End-User
13.1. Introduction
13.2. Cancer Research Institutes
13.3. Hospitals
13.4. Specialty Clinics
14. T-Cell Immunotherapy Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. T-Cell Immunotherapy Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. T-Cell Immunotherapy Market, by Country
16.1. China
16.2. United States
16.3. Japan
16.4. India
16.5. Germany
16.6. United Kingdom
16.7. Australia
16.8. France
16.9. South Korea
16.10. Italy
16.11. Canada
16.12. Russia
16.13. Brazil
16.14. Mexico
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Adaptimmune Therapeutics PLC
18.2. Alaunos Therapeutics, Inc.
18.3. Allogene Therapeutics, Inc.
18.4. Amgen Inc.
18.5. AstraZeneca PLC
18.6. Atara Biotherapeutics, Inc.
18.7. Autolus Therapeutics PLC
18.8. BioNTech SE
18.9. bluebird bio, Inc.
18.10. Bristol-Myers Squibb Company
18.11. CARGO Therapeutics, Inc.
18.12. CARsgen Therapeutics Holdings Limited
18.13. Cellectis SA
18.14. Celyad Oncology SA
18.15. Chimera Bioengineering
18.16. Dendreon Pharmaceuticals LLC
18.17. Eureka Therapeutics, Inc.
18.18. Fate Therapeutics, Inc.
18.19. Gilead Sciences, Inc.
18.20. Immatics N.V.
18.21. Innovative Cellular Therapeutics
18.22. Iovance Biotherapeutics, Inc.
18.23. Johnson & Johnson
18.24. LAVA Therapeutics N.V.
18.25. Lyell Immunopharma, Inc.
18.26. NeoTX Therapeutics Ltd.
18.27. Novartis AG
18.28. Oxford Vacmedix UK Limited
18.29. Poseida Therapeutics, Inc.
18.30. Sana Biotechnology, Inc.
18.31. TheraVectys SA
18.32. TScan Therapeutics, Inc.
18.33. Xenetic Biosciences, Inc.
List of Figures
FIGURE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL T-CELL IMMUNOTHERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2025 VS 2032 (%)
FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL TCR THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL TCR THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL TCR THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL TIL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL TIL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL TIL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ALLOGENEIC CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ALLOGENEIC CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ALLOGENEIC CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL AUTOLOGOUS CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL AUTOLOGOUS CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL AUTOLOGOUS CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BCMA TARGETING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BCMA TARGETING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BCMA TARGETING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CD19 TARGETING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CD19 TARGETING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CD19 TARGETING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CD22 TARGETING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CD22 TARGETING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CD22 TARGETING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL EX-VIVO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL EX-VIVO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL EX-VIVO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL IN-VIVO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL IN-VIVO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL IN-VIVO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL LUPUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BRAIN & CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BRAIN & CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BRAIN & CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 100. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 102. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 105. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 106. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 107. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 108. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 109. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 110. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 133. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 135. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 136. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 137. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 138. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 139. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 140. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 141. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 142. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 143. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 158. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 159. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 160. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 161. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 162. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 163. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 164. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 165. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 166. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 167. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 169. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 170. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 171. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 172. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 173. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 174. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 175. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 176. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 177. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 178. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 180. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 181. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 182. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 183. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 184. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 185. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 186. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 187. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 188. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 200. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 202. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 203. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 204. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 205. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 206. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 207. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 208. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 209. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 210. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 211. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 213. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 214. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 215. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 216. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 217. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 218. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 219. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 220. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 221. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 222. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 223. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 225. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 226. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 227. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 228. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 229. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 230. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 231. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 232. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 233. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 245. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 247. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 248. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 249. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 250. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 251. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 252. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 253. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 254. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 255. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 256. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 258. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 259. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 260. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 261. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 262. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 263. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 264. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 265. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 266. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 267. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 270. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 271. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 272. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 273. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 274. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 275. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 276. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 277. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 300. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 302. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 303. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 305. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 306. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 307. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 308. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 309. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 310. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 316. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 322. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 324. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 325. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 326. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 327. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 328. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 329. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 330. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 331. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 332. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 333. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 335. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 336. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 337. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 338. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 339. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 340. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 341. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 342. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 343. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 344. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 346. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 347. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2017-2032 (USD MILLION)
TABLE 348. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2017-2032 (USD MILLION)
TABLE 349. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 350. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 351. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 352. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 353. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 354. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 355. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 356. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION

Companies Mentioned

  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARGO Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • Celyad Oncology SA
  • Chimera Bioengineering
  • Dendreon Pharmaceuticals LLC
  • Eureka Therapeutics, Inc.
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics N.V.
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • LAVA Therapeutics N.V.
  • Lyell Immunopharma, Inc.
  • NeoTX Therapeutics Ltd.
  • Novartis AG
  • Oxford Vacmedix UK Limited
  • Poseida Therapeutics, Inc.
  • Sana Biotechnology, Inc.
  • TheraVectys SA
  • TScan Therapeutics, Inc.
  • Xenetic Biosciences, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.57 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.9 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Cellular Immunotherapy Market - Global Forecast 2026-2032 - Product Image

Cellular Immunotherapy Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Cellular Immunotherapy - Global Strategic Business Report - Product Image

Cellular Immunotherapy - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Cancer Immunotherapy - Global Strategic Business Report - Product Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Immunotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Immunotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Drug Pipelines
  • 150 Pages
  • Global
From

About the Market

T Cell Immunotherapy is a type of immune disorder drug that works by harnessing the power of a patient's own immune system to fight disease. It involves the extraction of T cells from a patient's blood, which are then genetically modified to recognize and attack cancer cells. This modified T cell is then reintroduced into the patient's body, where it can recognize and destroy cancer cells. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. T Cell Immunotherapy has been shown to be effective in treating certain types of cancer, and is being studied for its potential to treat other types of cancer and immune disorders. It is also being studied for its potential to treat autoimmune diseases, such as rheumatoid arthritis and type 1 diabetes. Some companies in the T Cell Immunotherapy market include Novartis, Kite Pharma, Juno Therapeutics, and Celgene. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.